Clinical Trial

Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)

Study acronym: CEFAZODIAL
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
In chronic hemodialysis patients, bacteremia is most commonly caused by dialysis catheter infections. It is estimated that the vast majority (52-84%) of these infections are due to Gram-positive cocci, particularly Staphylococcus aureus (21-43%). Penicillin M (oxacillin and cloxacillin in France) is the reference beta-lactam for the treatment of invasive methicillin-sensitive S. aureus (MSSA) infections, but has not shown a prognostic benefit in large retrospective cohorts comparing penicillin M and cefazolin, at the expense of more frequent adverse events. Dosage in the chronic hemodialysis population is unclear because it is based on old studies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-16; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2025-11-27
Status change: Not Yet Recruiting → Recruiting 2023-11-28
Trial Details
NCT Number NCT06093269
Lead Sponsor University Hospital, Tours
Conditions Hemodialysis Catheter Infection, Infection, Bacterial
Enrollment 32 participants
Start Date 2023-11-20
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-05